Skip to main content

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Objective

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caused by a multitude of organisms that traditionally evolve various mechanisms of resistance. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa, which is also important in other infections including wounds, burns and patients with medical devices, making it an important clinical target for the EU. In CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. We believe this will reduce antibiotic usage, optimize dosage and duration startegies as the therapy will be tailored to the actual individual patient needs. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CF MATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy. Simultaneously parallel human host-pathogen interaction studies in sputa, human gut microflora analysis and evaluation of murine exacerbation models will be performed. This will improve prescription practice and decrease antimicrobial usage and resistance.

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
Address
Western Road
T12 YN60 Cork
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 013 982
Administrative Contact
David O'connell (Dr.)

Participants (14)

THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU contribution
€ 955 241
Address
University Road Lanyon Building
BT7 1NN Belfast
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Colleen Spence (Mrs.)
UNIVERSITE PARIS DESCARTES
France
EU contribution
€ 199 638
Address
Rue De L Ecole De Medecine 12
75270 Paris Cedex 06
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rosaly Datchi (Ms.)
UNIVERSITY OF DUNDEE
United Kingdom
EU contribution
€ 384 410
Address
Nethergate
DD1 4HN Dundee
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Zoe Kidd (Mrs.)
UNIVERSITY OF WASHINGTON
United States
EU contribution
€ 490 994
Address
Brooklyn Avenue Ne 4333
98195 9472 Seattle Wa
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Christopher Goss (Prof.)
UNIVERSITATSKLINIKUM HEIDELBERG
Germany
EU contribution
€ 542 038
Address
Im Neuenheimer Feld 672
69120 Heidelberg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Thorsten Brietz (Mr.)
Agricultural Catchments Programme
Ireland
EU contribution
€ 363 797
Address
Oak Park
R93 Carlow
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mary O'brien (Ms.)
CLININFO SA
France
EU contribution
€ 107 962
Address
Rue De Gerland 99 Entree 7
69007 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patrick Chevarier (Mr.)
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Participation ended

Germany
EU contribution
€ 96 264
Address
Oskar Von Miller Ring 29
80333 Muenchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Birgit Fuchs (Mrs.)
PAPWORTH HOSPITAL NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 219 621
Address
Papworth Everard
CB23 3RE Cambridge
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Sophie Jackson (Mrs.)
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 132 746
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karolien Mariën (Ms.)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 224 520
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
Administrative Contact
Alix Pillot (Ms.)
HOSPICES CIVILS DE LYON
France
EU contribution
€ 82 341
Address
Quai Des Celestins 3
69002 Lyon
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Delphine Maurice (Mrs.)
UNIVERSITY HOSPITAL OF SOUTH MANCHESTER NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 68 586
Address
Southmoor Road Wythenshawe
M239LT Manchester
Activity type
Research Organisations
Administrative Contact
Lesley Howard (Mrs.)
ARTTIC
France
EU contribution
€ 117 608
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Dietz (Dr.)